Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2006
Business Overview: Neurocrine discovers, develops, and intends to commercialize drugs for neurological and endocrine-related diseases. The company has no approved products and relies on collaboration agreements (primarily with Pfizer and GlaxoSmithKline) and milestone payments for revenue. Its lead clinical program is indiplon for the treatment of insomnia, for which two New Drug Applications (NDAs) have been submitted to the FDA.
Key Financial Metrics
| Metric (in thousands) | Q1 2006 | Q1 2005 |
|---|---|---|
| Total Revenues | $19,476 | $11,864 |
| Net Loss | $(25,901) | $(18,830) |
| Loss Per Share (Basic & Diluted) | $(0.69) | $(0.51) |
| Operating Expenses | $47,070 | $31,211 |
| Cash and Cash Equivalents (End of Period) | $101,494 | $44,570 |
| Total Cash, Equivalents & Short-term Investments | $264,489 | $N/A (Not explicitly totaled in text) |
| Long-term Debt | $52,403 | $N/A |
| Accumulated Deficit | $(326,047) | $(300,146) |
Note: All figures are in thousands except per share data.
Material Changes vs. Prior Period
- Revenue Increase: Total revenue increased 64% to $19.5 million, driven primarily by the Pfizer collaboration. This includes $8.2 million in sales force allowance revenue (compared to $1.0 million in Q1 2005) and $5.9 million in sponsored development funding.
- Expense Surge: Operating expenses rose 51% to $47.1 million.
- R&D Expenses: Increased to $27.7 million due to higher personnel costs ($4.0 million increase) and the adoption of SFAS 123R ($2.1 million non-cash charge).
- SG&A Expenses: Increased significantly to $19.3 million (from $5.6 million) due to the implementation of a commercialization strategy, including $8.0 million in direct sales force costs and a $4.7 million non-cash stock-based compensation charge.
- Net Loss Expansion: Net loss increased by $7.1 million to $25.9 million. Management attributes the majority of this increase ($6.8 million) to the adoption of SFAS 123R (Share-Based Payment) effective January 1, 2006.
- Liquidity: Cash and cash equivalents more than doubled to $101.5 million, supported by a net increase in cash of $51.5 million, largely due to proceeds from stock option exercises ($13.9 million) and a prepayment from Pfizer for the sales force allowance.
Guidance, Outlook, and Risks
- Regulatory Outlook (Indiplon): The FDA has set a PDUFA action date of May 15, 2006, for both the capsule and tablet NDAs for indiplon. The company anticipates labeling that includes data from a driving study showing no impairment in next-day driving performance. Commercialization is contingent on FDA approval and subsequent DEA scheduling as a Schedule IV controlled substance.
- Collaboration Risks: The company relies heavily on Pfizer for funding and commercialization. Rights to co-promote Pfizer's Zoloft expire on June 30, 2006. If indiplon is not approved by this date, Pfizer may suspend sales force funding. Pfizer may also terminate the collaboration with 180 days' notice.
- Accounting Change: The adoption of SFAS 123R resulted in a significant non-cash expense of $6.8 million in Q1 2006. Future quarters will continue to recognize stock-based compensation expense, with $29.6 million of unamortized cost remaining for stock options.
- Capital Resources: Management believes existing capital resources ($264.5 million in cash and short-term investments) are sufficient to fund operations for at least the next 12 months. However, additional funding may be required for future R&D, and future equity financing would be dilutive.
- Discontinued Program: In March 2006, the company discontinued its APL-MS program for Multiple Sclerosis after Phase II results failed to meet the primary endpoint.
Investor Verification Checklist
- FDA Action Date: Verify the status of the indiplon NDA review and the May 15, 2006, PDUFA action date.
- Sales Force Funding: Monitor the expiration of Zoloft patent rights (June 30, 2006) and the potential impact on Pfizer's funding of the Neurocrine sales force if indiplon approval is delayed.
- Stock-Based Compensation: Review the impact of SFAS 123R on future quarterly earnings, noting the $29.6 million in unamortized stock option costs.
- Collaboration Terms: Assess the risks associated with the Pfizer collaboration, including termination clauses and the dependency on Pfizer for global commercialization.
- Cash Burn Rate: Evaluate the sustainability of the current cash position ($264.5 million) against the projected operating losses and capital expenditure requirements.